Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
[Delayed]RIBOMIC Announces IND Application for a Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment
RIBOMIC Announces Summary Report on Primary Endpoint for Phase II Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia
Summary of Non-Consolidated Financial Results for the Nine Months Ended December 31 2025(Based on Japanese GAAP)
RIBOMIC, Oct-Dec (3Q) Net Income Loss Narrows
New Substance Patent Application for Highly Active RBM-006 (Anti-Autotaxin Aptamer) and its Drug Impact in a Mouse Model of Diabetic Retinopathy
RIBOMIC, Net Income Forecast for the Fiscal Year Loss to Narrow
[Delayed]RIBOMIC Announces Continued Growth in Two-Year Follow-Up of Patients Responding to Achondroplasia Treatment Drug, Umedaptanib Pegol
Summary of Non-Consolidated Financial Results for the Six Months Ended September 30,2025(Based on Japanese GAAP)
RIBOMIC, First Half Ordinary Profit Loss Widens, Jul-Sep Ordinary Profit Loss Widens
RIBOMIC Presents Successful Phase II Clinical Trial of Achondroplasia Treatment at The Oligonucleotide Therapeutics Society International Conference
RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating Clinical Proof of Concept
Announcement Regarding Discovery of Therapeutic Effects of Umedaptanib Pegol in a Diabetic Retinopathy Model and New Patent Application for Use
RIBOMIC Announces the Sustained Efficacy in a Long-Term Administration Trial of Umedaptanib Pegol for Achondroplasia
Summary of Non-Consolidated Financial Results for the Three Months Ended June 30 2025(Based on Japanese GAAP)
RIBOMIC, Apr-Jun (1Q) Ordinary Profit Loss Narrows
[Delayed]RIBOMIC Plans to Initiate PhaseIII Clinical Trial of Umedaptanib Pegol for Achondroplasia in2026 Following the Ongoing PhaseII Clinical Trial
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
RIBOMIC, The Current Fiscal Year's Net Income to Widen
Summary of Non-Consolidated Financial Results for the Nine Months Ended December 31 2024(Based on Japanese GAAP)
RIBOMIC, Oct-Dec (3Q) Net Income Loss Widens